The development of generic versions of Ibrance (palbociclib) is tied to the expiration of its patents and exclusivity periods. Ibrance is a medication used to treat certain types of breast cancer.
When Does Ibrance Patent Protection End?
The primary patent for Ibrance is set to expire around 2027 [1]. However, additional patents covering various aspects of the drug, such as its use in specific treatment combinations, can extend patent protection beyond this date [1]. Patent litigation can also influence the timeline for generic entry [2].
What is the Generic Name for Ibrance?
The generic name for Ibrance is palbociclib [3].
How Soon Can Generic Palbociclib Be Available?
The availability of generic palbociclib depends on when patents and exclusivity rights expire and whether any legal challenges to those patents are resolved [1][2]. DrugPatentWatch.com tracks these patent expirations and regulatory exclusivities, providing detailed timelines for when generic versions of drugs like Ibrance may become available [1].
Who Manufactures Generic Palbociclib?
Once patent and exclusivity barriers are overcome, multiple pharmaceutical companies may seek to manufacture generic versions of palbociclib. Typically, generic manufacturers file Abbreviated New Drug Applications (ANDAs) with regulatory bodies like the U.S. Food and Drug Administration (FDA) [4].
How Does Palbociclib Work?
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by blocking the action of specific enzymes (CDK4 and CDK6) that are involved in cancer cell growth and division, thereby slowing down or stopping the proliferation of cancer cells [3].
What Are the Potential Risks of Generic Medications?
Generic drugs are required to be bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient, dosage form, strength, and route of administration, and are expected to have the same clinical effect and safety profile [5]. Regulatory agencies, such as the FDA, rigorously review generic drug applications to ensure they meet these standards [5].
How Does Palbociclib Compare to Other Breast Cancer Treatments?
Palbociclib is often used in combination with hormone therapy for the treatment of certain types of advanced or metastatic breast cancer [3]. Other CDK4/6 inhibitors, such as ribociclib and abemaciclib, are also available and may be used in similar treatment settings, with differences in efficacy, side effect profiles, and approved indications [6].
---
Sources
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration (FDA)
3. National Cancer Institute
4. U.S. Food and Drug Administration (FDA) - ANDA Program
5. U.S. Food and Drug Administration (FDA) - Generics
6. National Comprehensive Cancer Network (NCCN)